Explore insights by category
Drug Pipeline Insights Reports | Preparing for the GLP-1 Era | Regulatory updates | On-demand webinars | Podcasts | View all
Latest featured insights
Video
Hear how PBMs negotiate to deliver the lowest possible cost, benefiting plan sponsors and members alike.
Article
New tariffs on imported drugs are expected soon, which could mean higher prices and potential shortages.
Article
Meet Dr. Wig, Chief Clinical Officer for Optum Rx, and hear how we’re addressing cost and clinical trends in pharmacy.
Article
We know about the high prices for new drugs, but drug companies make most of their money from repeated small price increases on older drugs.
Drug Pipeline Insights Reports
Report
First self-administered Alzheimer's therapy shifts costs to pharmacy plans, plus first treatments for MS and bronchiectasis.
Report
New drugs for myasthenia gravis and hereditary angioedema will be easier to take, more effective, and add competition.
Report
Our report emphasizes new, next-gen and first-in-class treatments for cystic fibrosis, non-opioid treatment and GLP-1 drugs.
Preparing for the GLP-1 Era
Article
After revolutionizing care for diabetes and weight loss, GLP-1 drugs are being eyed for more. Can we afford it?
Solution or product page
Get the most from these pricey new obesity drugs by choosing the right coverage strategy and helping your members build lifelong habits.
Regulatory updates
Report
As legislation impacting PBMs ramps up again at the state level, the Trump administration signs drug pricing executive order in Washington, D.C.
Report
Learn what’s at stake for pharmacy benefits sponsors as federal oversight changes and state legislative sessions begin.
Article
In this conversation, learn the implications of new pharmacy legislation and rulemaking, and how you can manage your benefits effectively.
Latest on-demand webinars
On-demand webinar
From specialty pharmacy to drug affordability, our experts tackle your biggest pharmacy challenges.
Latest podcasts
Podcast
Listen to our resident experts discuss critical industry challenges and the solutions you need to control rising drug costs.